Abstract
Introduction Alzheimer’s disease (AD) is a devastating neurological disease that disproportionately affects women. This study aimed to investigate sex-specific single lipids associated with AD.
Methods Plasma samples from 841 participants, comprising 306 individuals with AD, 165 with mild cognitive impairment (MCI), and 370 cognitively healthy controls were curated from the AddNeuroMed cohort. Lipidomics identified 268 single lipids for each sample. We investigated sex-specific associations from lipid modules and single-lipids to AD and probed for causality with mediation analyses.
Results Three modules associated with AD in the female subset and one in the male subset (p < 0.05). In the female participants with AD, lipid families containing highly unsaturated fatty acids were reduced and those containing saturated lipids were increased (q-value < 0.05). The effects of unsaturated phospholipids on AD were not mediated via cholesterol, LDL or ApoB.
Discussion Women with AD have lower unsaturated blood lipid levels compared to controls.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding ARUK Senior Fellowship for this work was provided by Lundbeck Fonden by grant R344-2020-989, Petra Proitsi was funded by the ARUK through a Senior Research Fellowship ARUK-SRF2016A-3 C. We would also like to acknowledge the AddNeuroMed Consortium for providing the data.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The AddNeuroMed and Dementia Case Register study was approved by ethical review boards in each participating country (local ethical review board at University of Perugia, University of Toulouse, Aristotle University of Thessaloniki, Medical University of Lodz, University of Eastern Finland and University Hospital of Kuopio and King's College London).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The dataset analyzed in this study contains sensitive participant information and is not publicly available due to privacy concerns. However, qualified researchers may request access to the data through the AddNeuroMed consortium. All code used for data analysis is openly accessible via GitHub: https://github.com/Asger-W/AddNeuroMed-Lipidomics.
